Neurology

Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences

ZUG, Switzerland, Sept. 01, 2025 (GLOBE NEWSWIRE) -- Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis…

3 months ago

Data4Life announces the appointment of Dr. Ben Illigens as new CEO by the Hasso Plattner Foundation

POTSDAM, Germany, Sept. 1, 2025 /PRNewswire/ -- Data4Life announces that the Hasso Plattner Foundation, as the supporting foundation of the organization,…

3 months ago

FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

LEQEMBI IQLIK is the first and only anti-amyloid treatment to offer an at-home injection to help patients and care partners…

3 months ago

Can-Fite Reports H1 2025 Financial Results and Clinical Update

Ramat Gan, Israel, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company…

3 months ago

VALERIS NAMES JONATHAN SAVAGE CHIEF PRODUCT OFFICER

JEFFERSONVILLE, Ind. and MORRISVILLE, N.C., Aug. 26, 2025 /PRNewswire/ -- Valeris, a fully integrated life sciences commercialization partner that provides…

3 months ago

Bausch Health Announces Extension of DURECT Corporation Tender Offer to September 10, 2025

LAVAL, QC AND CUPERTINO, CA / ACCESS Newswire / August 26, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global,…

3 months ago

Develop Health Raises $14.3M to Automate Prior Authorization and Medication Access Using GenAI

The GenAI-powered platform automates benefit verification, prior authorization, and payer follow-up to reduce treatment delays and manual burdenSAN FRANCISCO--(BUSINESS WIRE)--Develop…

4 months ago

REPEAT — Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts

Includes $36 million line of credit and potential $14 million private placement WARREN, N.J., Aug. 19, 2025 (GLOBE NEWSWIRE) --…

4 months ago

BioNxt Fast-Tracks U.S. Patent for MS Drug and Secures Broad Platform IP Covering Autoimmune Neurology Pipeline

VANCOUVER, BC / ACCESS Newswire / August 20, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a…

4 months ago